|
Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance Measurements
RECRUITINGSponsored by M.D. Anderson Cancer Center
Actively Recruiting
SponsorM.D. Anderson Cancer Center
Started2026-09-16
Est. completion2027-12-31
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07855627
Summary
To find out whether the BIA test can help identify participants with IBC who are at risk for developing lymphedema.
Eligibility
Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Eligibility Criteria All women≥18 years old with newly diagnosed inflammatory breast cancer without prior breast/axillary surgery who are eligible for standard of care (NST, MRM, and radiation therapy). Exclusion Criteria Prior breast/axillary surgery. Participants with pacemakers or other implanted electronic medical devices. Participants with implanted metallic material. All vulnerable populations, including children, pregnant women, and cognitively impaired adult
Conditions6
Bioimpedance MeasurementBreast CancerCancerInflammatory Breast Cancer (IBC)LymphedemaPreoperative
Interventions1
Locations1 site
Find trials near these locations
Related trials
- A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer — Sun Yat-sen University
- Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer — Jiuda Zhao
- Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer — Sichuan Cancer Hospital and Research Institute
- Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer — Sun Yat-sen University
- Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study — Qilu Hospital of Shandong University
- Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC) — Rutgers, The State University of New Jersey
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorM.D. Anderson Cancer Center
Started2026-09-16
Est. completion2027-12-31
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07855627